<< Tumour suppressor gene family may be key to new colon cancer drugs | New medical device indentifies abnormal heart rhythms called atrial fibrillation >>
Read in | English | العربية | हिन्दी | Norsk

Pacemaker-type device and medicines reduce hospital stays and death rates

Published on May 20, 2004 at 9:09 PM · No Comments

A nationwide clinical trial of more than 1,600 heart failure patients showed that when medicines are combined with the use of a pacemaker-type device that resynchronizes both sides of the heart, hospital stays and death rates drop significantly. The University of Rochester Medical Center Cardiology Department was the only site in the Finger Lakes region, and was among 128 centers nationwide that took part in the research, which is published in the May 20 issue of New England Journal of Medicine.

The New England Journal devotes much of this week’s edition to several clinical studies of these devices, and raises the question of whether their use should be expanded to include a larger pool of patients.

“This research opens up a new avenue for heart failure patients,” says Chang-seng Liang, M.D., UR professor of Medicine and one of the lead investigators in Rochester. “The heart disease process is very complex, and treating patients is not a one-size-fits-all proposition. Being able to offer this gives us more options.” The co-investigator was David Huang, M.D., assistant professor of Medicine.

For Sharon DeCarlo of Rochester, participating in the study has brought benefits. DeCarlo, 38, a secretary at Strong Cardiology Associates, knew the warning signs of heart disease but had trouble believing her fatigue and shortness-of-breath could be attributed to something that serious. “Young, healthy women are like that – not in a million years did I think I had heart trouble,” she says. “You just shrug things off.”

But an escalation of symptoms and several tests showed she suffered from a dilated cardiomyopathy plus a left bundle branch block, an electrical malfunction that doesn’t allow both chambers of the heart to beat together. Doctors speculated that a virus had damaged her heart, perhaps months or years earlier.

DeCarlo enrolled in the clinical trial, called Comparison of Medical Therapy, Pacing and Defibrillation in Chronic Heart Failure or COMPANION, and surgeons implanted a cardiac resynchronization therapy (CRT) device in her chest. She also received heart medications, lost 25 pounds and began exercising again.

“I’m doing fine. It’s just the simple things like being able to run down to the laundry room and back upstairs without getting winded,” DeCarlo said. “I feel very lucky.”

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading